When Congress enacted the No Surprises Act (NSA), the primary objective was straightforward: protect patients from unexpected out-of-network medical bills. Since implementation in 2022, however, the law has created a complex framework for resolving payment disputes between providers and payors through the Federal Independent Dispute Resolution (IDR) process.
What began as a well-intentioned arbitration mechanism has evolved into a system burdened by millions of disputes, operational inefficiencies, administrative complexity, and mounting costs. Recognizing these challenges, the Departments of Health and Human Services, Labor, Treasury, and the Office of Personnel Management recently finalized significant reforms to the Federal IDR process. While much of the discussion surrounding these changes has focused on hospitals and physician organizations, laboratories and diagnostic providers should pay close attention. Several provisions in the final rule could materially impact dispute management workflows, reimbursement strategies, and administrative costs.
A System Under Pressure
Since the Federal IDR process launched in April 2022, more than five million disputes have been submitted, far exceeding original government projections. The volume has created substantial backlogs, increased costs for participating organizations, and generated frustration among both providers and payors.
For laboratories, pathology groups, and other diagnostic providers that occasionally find themselves involved in out-of-network reimbursement disputes, the administrative burden associated with pursuing IDR has often outweighed the potential financial recovery. As a result, many organizations have simply absorbed underpayments rather than invest the resources necessary to challenge them.
The latest reforms are intended to address these challenges by improving efficiency, increasing transparency, and lowering barriers to participation.
Lower Costs May Encourage More Dispute Participation
One of the most notable changes is the reduction of the Federal IDR administrative fee from $115 to $15 per party, per dispute.
While this may appear modest, the reduction could significantly alter the financial equation for providers evaluating whether to pursue arbitration. For laboratories operating on increasingly narrow margins, particularly those performing specialized diagnostic testing, lowering the cost of entry may make it more practical to challenge inappropriate reimbursement determinations.
Organizations that previously dismissed smaller disputes as economically unfeasible may now find it worthwhile to pursue recovery through the Federal IDR process.
Expanded Batching Could Be a Game Changer for Laboratories
Perhaps the most impactful provision for diagnostic providers is the expansion of batching flexibility.
Historically, restrictive batching requirements forced providers to submit multiple disputes even when claims involved similar services. This increased administrative effort, delayed resolution timelines, and elevated costs.
The final rule now permits qualified items and services to be batched under broader criteria, including pathology and laboratory services that fall within the same Category I CPT code section. In addition, up to 50-line items may be included within a single batched dispute.
For laboratories managing multiple related claims, this change could substantially reduce the administrative burden associated with dispute preparation, submission, and tracking. Instead of treating each service line as a separate arbitration event, organizations may be able to consolidate disputes into a more efficient and cost-effective process.
This is particularly important as diagnostic testing continues to become more complex and specialized, often involving multiple services associated with a single patient encounter.
Greater Transparency Between Providers and Payors
Another persistent challenge within the No Surprises Act framework has been inconsistent communication regarding payment determinations.
Providers frequently receive remittance information that lacks sufficient detail to determine whether a claim qualifies for IDR or to understand the rationale behind a reimbursement decision.
The final rule addresses this issue by requiring health plans and issuers to provide standardized Claim Adjustment Reason Codes (CARCs) and Remittance Advice Remark Codes (RARCs) when communicating payment decisions.
This additional transparency may help laboratories more quickly identify potentially disputable claims, understand denial rationales, and determine whether arbitration is an appropriate next step.
For revenue cycle teams, these requirements may also support greater automation opportunities by allowing organizations to systematically identify claims eligible for escalation.
Operational Readiness Will Matter
The reforms also introduce new procedural requirements surrounding open negotiation activities, including mandatory portal-based submissions and response timelines.
Organizations that rely on manual workflows may find compliance with these requirements increasingly difficult as dispute volumes grow. Success will depend on having the operational infrastructure necessary to identify eligible claims, manage negotiation deadlines, track dispute status, and maintain supporting documentation.
As regulatory requirements become more prescriptive, reimbursement teams will need greater visibility into denial trends, reimbursement patterns, and dispute outcomes.
This is where advanced analytics and workflow automation become increasingly important. Organizations that can quickly identify underpayments, track negotiation activity, and prioritize high-value disputes will be better positioned to maximize recovery while minimizing administrative burden.
Looking Ahead
The latest Federal IDR reforms represent an acknowledgment by regulators that the original process required modernization. By reducing fees, expanding batching opportunities, improving transparency, and introducing a centralized IDR Gateway platform, federal agencies are attempting to create a more efficient and scalable dispute resolution framework.
For laboratories and diagnostic providers, these changes present both opportunities and responsibilities. Organizations that proactively evaluate their dispute management strategies, strengthen reimbursement analytics, and prepare for evolving operational requirements will be best positioned to benefit from the reforms.
The No Surprises Act remains a dynamic and evolving regulatory landscape. While these changes are unlikely to eliminate payment disputes altogether, they may provide laboratories with more practical and cost-effective tools to address them when they occur.
About Clarisa Blattner, CCS, CPC
Clarisa Blattner is the Senior Director of Revenue and Payor Optimization at XiFin, Inc. She serves as a subject matter expert in revenue cycle management (RCM) and payor and market strategies, focusing on achieving operational efficiencies and maximizing revenue. With over 25 years of experience in the healthcare sector, Clarisa has an extensive background in revenue cycle management, particularly within the healthcare industry. Previously, she oversaw the billing and reimbursement operations for the outsourced billing department
